

CORRECTION

Open Access



Correction to: LncRNA PVT1 up-regulation is a poor prognosticator and serves as a therapeutic target in esophageal adenocarcinoma

Yan Xu^{1,2}, Yuan Li^{1,2}, Jiankang Jin¹, Guangchun Han³, Chengcao Sun⁴, Melissa Pool Pizzi¹, Longfei Huo¹, Ailing Scott¹, Ying Wang¹, Lang Ma¹, Jeffrey H. Lee⁵, Manoop S. Bhutani⁵, Brian Weston⁵, Christopher Vellano⁶, Liuqing Yang⁴, Chunru Lin⁴, Youngsoo Kim⁷, A. Robert MacLeod⁷, Linghua Wang³, Zhenning Wang^{2*}, Shumei Song^{1*} and Jaffer A. Ajani^{1*}

Correction to: Mol Cancer (2019) 18:141
<https://doi.org/10.1186/s12943-019-1064-5>

Following publication of the original article [1], the authors identified minor errors in image-typesetting in Fig. 3; specifically the left hand side of Fig. 3d.

The corrected figure is given below. The correction does not have any effect on the results or conclusions of the paper.

Author details

¹Departments of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.

²Department of Surgical Oncology and General Surgery, First Hospital of China Medical University, Shenyang 110001, People's Republic of China.

³Departments of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. ⁴Departments of Molecular & Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. ⁵Departments of Gastroenterology&Hepatology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

⁶Center for Co-Clinical Trial, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. ⁷Ionis Pharmaceuticals, Inc., 2855 Gazelle Court, Carlsbad, CA 92010, USA.

Published online: 25 March 2021

Reference

1. Xu Y, Li Y, Jin J, et al. LncRNA PVT1 up-regulation is a poor prognosticator and serves as a therapeutic target in esophageal adenocarcinoma. *Mol Cancer*. 2019;18:141 <https://doi.org/10.1186/s12943-019-1064-5>.

The original article can be found online at <https://doi.org/10.1186/s12943-019-1064-5>.

* Correspondence: josieon826@sina.cn; ssong@mdanderson.org; jajani@mdanderson.org

²Department of Surgical Oncology and General Surgery, First Hospital of China Medical University, Shenyang 110001, People's Republic of China

¹Departments of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA

Full list of author information is available at the end of the article



© The Author(s). 2021 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.




Fig. 3 PVT1 suppression by PVT1 ASOs inhibits EAC cells growth in vitro and in vivo. **a** PVT1 expression in EAC cell lines (FLO1, SK-GT-4, JHESO, and OE19) and normal esophageal epithelial cell line HET-1A were determined by realtime qPCR analysis. **b** PVT1 expression was analyzed by qPCR in PVT1 ASOs treated EAC cell lines. PVT1 specific antisense oligonucleotides (ASO4 and ASO5) reduced PVT1 expression in dose-dependent manner in three EAC cell lines. **c** and **d**. Inhibition of PVT1 by ASOs significantly suppressed colony formation (**c**) and decreased cell invasion (**d**) in both JHESO and OE19 cells in two individual PVT1 ASOs respectively. **e** Average tumor volume in mice that treated with PVT1 ASO4 or control ASO via subcutaneous injection for 3 weeks (left). Actual tumor weights were retrieved from the mice at the termination of the experiment (middle). Representative tumors after scarified were shown (right). **f** The expression of PVT1 in mouse tumor tissues measured by qPCR has been shown significant reduction upon treatment with PVT1 ASO4 compared to the control group. Error bars, mean \pm SEM. *, $P < 0.05$; **, $P < 0.01$